Medically-Assisted Treatment (MAT)
John W. McIlveen, Ph.D., LMHC
Operations and Policy Analyst/State Opioid Treatment Authority (SOTA)
Manager/Health Professionals’ Service Program (HPSP)
Oregon Health Authority
Health Systems Division/Operations & Policy
500 Summer St. NE E86
Salem, OR 97301
Oregon Health Authority- Opioid
What is MAT?
Buprenorphine for Opioid Use Disorder: SAMHSA Advisory
Medication-assisted treatment (MAT) is an important part of an effective response to opioid use disorder and has been found to reduce morbidity and mortality, decrease overdose deaths, reduce transmission of infectious disease, increase treatment retention, improve social functioning, and reduce criminal activity.
This Advisory reviews current information on the use of sublingual and transmucosal buprenorphine for MAT of opioid use disorder. Topics include new formulations of buprenorphine, the effectiveness and safety of buprenorphine treatment, contraindications and cautions (including medication interactions), informed consent and treatment agreements, treatment monitoring, and indications of diversion and misuse.
NDCI Web-Training Resource for Drug Treatment Courts
- Module 1: What are Substance Use Disorders?
- Module 2: What is Medication-Assisted Treatment?
- Module 3: Medication Assisted Therapies: Using Medication for Treatment of Opioid and Alcohol Disorders?
- Module 4: Strategies to Reduce Diversion of Abusable Medications
- Module 5: Primary Components of Evidenced Based Treatments for AddictionsT
- Module 6: Pros and Cons of MAT
- Module 7: Drug Courts and MAT: The Legal Landscape
- Module 8: Long-term Opioid Therapy and Chronic Pain: Understanding and Mitigating Risk
- Module 9: Interpretation of Drug Testing Results in Medication-Assisted Treatment (MAT)